SF and Silicon Valley: Drop the Incrementalism and Invest in True Innovation

“Just as energy is the basis of life itself and ideas the source of innovation, so is innovation the vital spark of all human change, improvement and progress”—Theodore Levitt

I have lived in the Seattle area for many years, and I spend a fair amount of time interacting with senior executives and fellow venture capitalists in San Francisco and Silicon Valley. I’ve studied what makes the Bay Area region one of the leading technological and commercial centers in the world. It has the entrepreneurial spirit and vast networks of capital and human resources that makes new company formation doable. We in the Northwest look at how Silicon Valley has managed to establish an entrepreneur-friendly ecosystem and how, compared with other regions, it appears to more easily translate discoveries from research laboratories into valuable commercial products. Thinking about how to create this environment reminds me of the quote from Theodore Levitt (a former Harvard Business School Professor), who emphasized that innovation is the key catalyst to promote sustainable change, improvement and progress.

If we want to achieve this goal, we need to foster an enduring ecosystem for innovation so that it can resist the unpredictable ups and downs of the marketplace.

Focusing on true innovation should not come as a surprise to those in Silicon Valley or San Francisco. What we think of today as Silicon Valley emerged largely through early innovations that came from developing and manufacturing advanced electronic components, microwave technology, and semiconductors. Major innovations in life sciences—like the discovery of genetic engineering techniques—resulted in the creation of an entirely new biotechnology industry (led in the Bay Area by Genentech) that revolutionized the way in which novel medicines for human diseases would be discovered and developed.

Following in the footsteps of this tradition, Bay-Area entrepreneurs and VCs should consider doing the following three things to foster a more stable and sustainable environment for innovation:

Invest in True Innovations, Not ‘Me-too’ Products: Talented entrepreneurs need to invest their time and energy in identifying the most revolutionary technologies and building companies that will find the most capital-efficient way to commercialize these technologies to solve our most vexing problems in the IT, life science, and energy sectors. This means steering clear of “me-too” type technologies and focusing on those true technical discoveries that can make more than just incremental improvements. This also implies that entrepreneurs need to

Author: Thong Le

Thong Q. Le serves as Chief Executive Officer (CEO) of Accelerator Corporation. With more than 16 years of experience in identifying, investing, managing, and successfully exiting numerous seed and early-stage investments, Mr. Le is positioned to grow and expand the Accelerator investment model. He currently serves as CEO and Director of Acylin Therapeutics and Oncofactor Corporation, and is a Board Observer at AnswerDash and Cardeas Pharma. Prior to becoming CEO at Accelerator, Mr. Le served as a Managing Director at WRF Capital, the venture capital investment arm of Washington Research Foundation in Seattle, WA. During his 13-year tenure at WRF Capital, Mr. Le played a significant role in the early sourcing, financing, and development of numerous start-up companies, including Alder Biopharmaceuticals (NASDAQ: ALDR), Corus Pharma (acquired by Gilead Sciences), Halosource (LSE: HALO.L), Hyperion Therapeutics (Nasdaq: HPTX), Lumera (NasdaqNM: LMRA), Performant (acquired by Mercury Interactive), Pathway Medical Technologies (acquired by MEDRAD), and VLST (asset acquisition by major international pharmaceutical company). He also led WRF Capital’s investments in Accelerator, AnswerDash, ARZEDA, Cardeas Pharma, Resolve Therapeutics, and Uptake Medical, all companies where he was actively involved in establishing as a founding or early investor. Prior to joining WRF Capital, Mr. Le was the founder, president and CEO of MiniMeals, Inc. and a consultant for Capital Management Consulting, Inc. Earlier, he was at Raymond James & Associates, Singer & Xenos Investment Management Company and Capital Management Group LLC, a private investment firm specializing in biomedical ventures. Mr. Le completed post-graduate studies at the Templeton College of Oxford University and earned a bachelor of arts cum laude in government from Harvard University. He currently serves on the executive boards of the Evergreen Venture Capital Association (EVCA), the Washington Biotechnology & Biomedical Association, and the Washington Global Health Fund. He was previously named one of the region’s “40 Under 40” by the Puget Sound Business Journal.